Medical Education

Medical Education Grants

Jazz Pharmaceuticals (Jazz) is committed to improving patient outcomes and providing support in compliance with local regulations.

Therapeutic Areas of Interest

Neuroscience

Narcolepsy (US and Canada Only)

Educate on the burden of illness and symptoms associated with narcolepsy
- The increased risk and burden of CV/CM comorbidities
- Lifelong management of disease
Educate on a holistic treatment approach that addresses narcolepsy symptoms and associated risk and comorbidity burden
Educate on the impact of treatments on sleep instability and sleep quality in narcolepsy patients
Educate on the potential impact of excessive sodium intake on near- and long-term health and the relevant risk in narcolepsy patients
Educate on the importance of diagnosing narcolepsy in underserved care settings and vulnerable populations

Idiopathic Hypersomnia (US and Canada Only)

Screening, differential diagnosis, and management of Idiopathic Hypersomnia
Burden of symptoms associated with Idiopathic Hypersomnia (eg, sleep inertia, EDS, prolonged sleep duration) and the impact of treatment, including efficacy, safety, and quality of life considerations,
The clinical comorbidity burden of Idiopathic Hypersomnia, including cardiovascular/cardiometabolic comorbidities, and impact of treatment choices
The potential impact of excessive sodium intake on health and relevance of this risk in Idiopathic Hypersomnia patients

Epilepsy

Timely screening, identification, diagnosis, and optimal seizure management of Lennox-Gastaut Syndrome (LGS) and other developmental and epileptic encephalopathies (DEEs), especially in adult patients
Comprehensive management of patients with DEEs including symptoms beyond seizures
Improving adherence to and persistence with antiseizure medications in DEEs including initiation titration, AE and DDI management and optimizing efficacy

Cannabinoid Science

Education on the complexity of cannabinoid science to better understand the importance of high-level evidence to assess cannabinoid-based drugs.
Evaluation of differences in evidence/data presented for cannabinoid-based drug products submitted for regulatory approval (including, for example FDA, EMA, MHRA, PMDA).
Assessments of the risk profiles for under-regulated cannabinoid products.

Oncology

Acute Lymphoblastic Leukemia (ALL)

The biology of immune response, differentiation and management of asparaginase hypersensitivity reactions and the outlining impact and burden on safety and efficacy
The importance of completing treatment and potential safety or other concerns associated with current clinical mitigation strategies for hypersensitivity reactions
Recognition and management of unique asparaginase toxicities in the pediatric, adolescent and young adult patient population
Management of pediatric and adolescent/young adult ALL/LBL with asparaginase (e.g., monitoring, PK, safety, clinical value)
Pediatric inspired protocols in the young adult and adult population
The efficacy and clinical benefits of short-acting asparaginase formulation in ALL/LBL
Asparaginase therapies and combinations beyond ALL/LBL
Best practices for multidisciplinary team in educating pediatric and AYA patients and their caregivers to support informed decision-making.
Evidence-based managed care considerations for ALL management

Acute Myeloid Leukemia (AML)

The role of intensive chemotherapy in the treatment of high-risk AML
Timely diagnosis and treatment initiation in high-risk AML subgroups (eg, AML-MRC, tAML)
Different technologies for the delivery of high-risk AML treatments
Depth of response, real world data and long-term outcomes
Appropriate management of high-risk AML in the inpatient and outpatient settings
The AML treatment paradigm (eg, induction, consolidation, combination therapy, maintenance therapy) and patient management
Clinical and economic burden of high-risk AML
Evidence-based managed care considerations for AML therapies

Gastrointestinal (GI) Cancers

The rationale of targeting HER2 over-expression in GI cancers
HER2 biomarker testing and utilizing evidence-based scoring best practices (e.g., CPS testing) in patient selection and developing personalized treatment plans
Current and emerging therapies including:
- Efficacy
- Safety
- Mechanism of Action
Treatment selection and sequencing strategies for HER2-targeting therapies
Evidence-based best practices in monitoring and managing potential side effects
Evidence-based managed care considerations for therapies targeting HER2 in BTC and GI malignancies

Small Cell Lung Cancer (SCLC)

Second-line treatment options and therapy sequencing in SCLC management
Current considerations in first-line maintenance and second-line SCLC therapies including:
- Efficacy
- Safety
- Mechanism of action
- Evidence-based best practices
Best practices for patient management in first and later lines of SCLC treatment
Evidence based managed care considerations for SCLC management (1L and subsequent therapies)

Veno-Occlusive Disease (VOD)

Recognition, incidence, risk factors, diagnosis and early intervention in VOD/SOS
VOD/SOS diagnostic criteria, diagnostic techniques, radiologic findings and severity grading in both adult and pediatric patients
Pathophysiology, progressive nature and life-threatening complications of advanced VOD/SOS and other endothelial related complications
Efficacy, safety and mechanism of action of current and emerging novel therapies and patient management in the treatment of VOD/SOS
Clinical and economic burden of VOD/SOS and other post-transplant complications associated with endothelial cell damage

Eligible educational grant applicants include the following (not an exhaustive list):

Medical Schools
Medical Associations/Medical Societies
Hospitals/Medical Centers
Medical Education Providers

This system is currently accepting requests for medical education meetings, conferences, or symposia; medical center grand rounds lectures; fellowships; enduring medical education activities; and similar educational activities.

In Europe & International (EUR/INT) the system is also accepting requests for medical grants as allowed by local regulations.

The following grant requests are not covered by the educational grant request process: requests for funding educational activities that are promotional in nature (e.g., brand-specific promotional speaker activities); requests for funding activities related to promotion of a commercial product (e.g., commercial exhibits); and operational funding for patient advocacy organizations.

How to Apply

Grant requests should be submitted using the Jazz Pharmaceuticals Request Management System.
All grant requests should be received by Jazz in complete form at least 60 days prior to the commencement of the educational activity for consideration.
The system will guide applicants through the process of determining the request type and the required documents for each request.
Jazz Pharmaceuticals does not control or influence the content of programs or the selection of speakers, authors, or faculty planners.
All decisions regarding support are at the discretion of Jazz and will be communicated by email.
Submission of a request does not guarantee support.
For more information, or for questions regarding the status of a grant request, please email mededgrant@jazzpharma.com.